Greg, is good community. excited Thank this investment you, team and morning to Abeona you The our to morning. be with
and MPS type as A, shareholder or known continuing gene providing have value. novel drive the RDEB; are MPS options. our B, currently also on of portfolio IIIB; treatment the our as long-term well epidermolysis as programs early clinical cell patients known pursuing Sanfilippo and bullosa, programs growth of committed term, development In Syndrome and at to toward remain we our approved Syndrome near- We, Abeona, advanced recessive also Abeona's and therapies to focused unlock no as Sanfilippo stage near dystrophic type who and to IIIA; as in
for ongoing have Phase VITAL Enrollment in date. VITAL III Three EB-XXX First, starting the our study EB-XXX for program. is to with patients treated RDEB. pivotal been
VITAL RDEB the COVID-XX restrictions concerns anticipate enrollment would XX total. target the sites line half safety. approximately reminder, about pandemic, the completing XX for for impact in treated is we the study upon depending enrollment, from XX for data to travel Based anticipate in a and/or and staff XXXX, study currently first with in current As enrollment We study the the of VITAL XXXX. large the including patient on late VITAL chronic in completing expectation wound patients top
be patient. the a X will last-treated endpoint months As post reminder, pivotal
safety data IIIA given with of as for from I/II Transfer for investigational was Let's XxXX^XX to afflicted the of encouraging report our IIIA efficacy B. move to these in Phase for which A of of in XX through with IIIA, ABO-XXX to as respective treatment on decision our at have the adeno-associated enrollment back patients virus, the a study lack our X MPS and XXXX kilogram. I'm the Abeona, been including Transfer clinical patients cohort and cohort specifically the enrolling MPS Transfer therapies, made the quarter Transfer were Transfer XX respectively. options limit continue proud dose MPS We ABO-XXX XX in XX is on genomes target the refer based to and Total IIIB, trials trials as patients, vector who and standpoint. enrollment X date patients, dosed A for has A into patients per A that first to higher well study We, gene AAV, to from achieved.
B kilogram. quarter cohort study XX of MPS first and is COVID-XX X range IIIB. XxXX^XX in XXXX A patients XX enrollment X anticipate XX has dosed the for since to genomes including target treatment. X. B We Transfer patients, study patients to B a travel ability have Transfer of undergo the to is in in Transfer cohort dosed, which for the vector To reminder, Turning impacted study, completing some date, upper patients' per been dose
Regarding treated in between been who Transfer we months X dose reported the have study. X years the the patients X and in of data preservation young neurocognitive A patients showing previously among skills study, of cohort had XX post-treatment treated
for than a additional X. These very assessment years, gathering we medical to data plan some present plan near-term future X X, up X.X are each meeting. cohort years neurocognitive follow-up the of patients between these more are from We and high-dose age and -- to about with to patient at X results
to The age additional which indicates the to in at patients prevent potential terms start normalization tend in thereafter versus history as of skills neurodegeneration years X XX evidence further plus patients in in natural MPS provide we of will neurocognitive dosing. these plateau IIIA disease, could This each year, behavioral important regress a of of preserve new MPS of very be patients the levels point they ABO-XXX's skills, and acquisition young and time minimal will of gaining later of a and between this post to the data XX skills. months neurocognitive IIIA their and data to be looking with
MPS EMA's path a Based IIIA our of during X-year along for MPS the last we of the previous approval presented Medicinal after Use, with under PDCO, kickoff on Pediatric plan review toward for meeting, medical anticipate ABO-XXX of for which program, our accelerated in the needs. we study. therapies completion quarter, Transfer for treated Human for from promising third the IIIA the of follow-up neurocognitive EEU the input of Products the Committee application CHMP, meeting offers disease targeting ABO-XXX and the unmet the PRIME In conditional assessment the and registration submitting a patient A for marketing authorization Committee EMA,
place quarter path of a for the and in IIIA. ABO-XXX our update on With quite regard the lines discuss year the course, targeting down they've We're early depending regulatory next ABO-XXX take the have availability first to of FDA's meeting an engaged U.S. to the States. the to with to XXXX, time filing, we We as bogged MPS FDA on ongoing for look pandemic. plan in United COVID-XX and providing been forward potential
will manufacturing operation production onward Cleveland, the costs. course, is provide quality, in-house to our used manufacturing. while at of Process activities, in great expected and our Abeona development reducing of of with time, at moving and the manufacturing to supply ongoing Abeona for chain, of enable one our same EB-XXX strength control technical increased the This facility retrovirus product Next, of areas Therapeutics. for Ohio, is GMP
to supply commercial ABO-XXX, gene our development products, In activities in-house enable therapy are addition, of manufacturing process ongoing. for and ABO-XXX
the Jay As manufacturing. question-and-answer Officer, if Bircher, arise Technical around join our us portion, will Operations Greg indicated, during any questions our Chief
therapy patients payments assets and Batten's Next, in to also while excited achievement-based turning this to for opportunity infantile We known work unlock ABO-XXX allow earlier-stage as partnerships for clinical, We're an also therapy CLNX of expected into in and near-term programs plus providing updates. to These partnership AAV-based to X milestones corporate success value noncore are Abeona partnerships entered disease, syndrome. to for regulatory gene future us Therapies for Gene faster. to with propel gene net products strategic royalty-based sales. on Taysha disease, these to share with Rett order to these sales the through in
both the me Ed call today's say of I words to our and excites assumed great about over near Before I starts term. to a new with leadership. a foundation in the significant operating portion people Abeona while and Abeona has capability, wanted which turn their for I've financial place, as role robust few science our discussion, pipeline, deep what a and about my longer
improved using AAV-based novel the developing capsids intend are AIM and In develop capsids different platform. chimeric researching to therapies monogenetic AAV disorders. indications, continue capable addition including programs, to Abeona's capsids gene targeting tissue clinical our various technology retinal we for to We and next-generation of from
Our work for Board to toward Abeona, unmet exciting future. our as an and we future are medical shape shape needs. these Directors committed It's senior the future patients, our company's and the addressing we time of as we of management fully
of With changes organizational proud to minimized in announced I'm team. report distraction the have the we October,
the We forward. am our to this going privileged of lead to have group unlock and pipeline, and our continued to I stay potential people poised
I'm for a Officer, you time And turn thank your for Accounting Carr, update. please. today. that, to this going Ed, over with I financial Chief to our Ed
